Improvements in biochemical activity and affinity assays

Kinases remain a highly pursued drug target for numerous therapeutic areas [95]. In addition to the primary screen, selectivity profiling of 

Having said all this, a recent report from a major pharmaceutical company with one of the largest reported screening collections revealed that just over 50% of their current lead optimization efforts invoke a fast follower approach [114]. Why is this One might speculate that as most companies work on the same targets these days chemists find it easier to patent bust than wait for the results of an HTS campaign which may take months to develop. Possibly, when more novel targets are identified, HTS of enhanced collections will deliver upon the promise that they hold. 

Kevin J. Hodgetts, Kerry J. Combs, Amy M. Elder and Geraldine C. Harriman 

Over the last five decades, researchers have utilized the unique characteristics of the fluorine atom in the creation of new drugs that have impacted the quality of life of many individuals. No other substituent has captured the imagination of medicinal chemists to the extent that 

Annual Reports in Medicinal Chemistry, Volume 45 ISSN 0065-7743, DOI 10.1016/S0065-7743(10)45026-5 

---